Wong SL - Search Results

1

Modeling the impact of patient treatment preference on health outcomes in relapsing-remitting multiple sclerosis.

van Eijndhoven E, Brauer M, Kee R, MacEwan J, Mucha L, Wong SL, Durand A, Shafrin J. van Eijndhoven E, et al. Among authors: wong sl. J Med Econ. 2020 May;23(5):474-483. doi: 10.1080/13696998.2019.1711100. Epub 2020 Jan 21. J Med Econ. 2020. PMID: 31903813 Free article.

2

Relapse outcomes, safety, and treatment patterns in patients diagnosed with relapsing-remitting multiple sclerosis and initiated on subcutaneous interferon β-1a or dimethyl fumarate: a real-world study.

Ernst FR, Barr P, Elmor R, Wong SL. Ernst FR, et al. Among authors: wong sl. Curr Med Res Opin. 2017 Dec;33(12):2099-2106. doi: 10.1080/03007995.2017.1380616. Epub 2017 Sep 28. Curr Med Res Opin. 2017. PMID: 28906152

3

Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis.

Siddiqui MK, Khurana IS, Budhia S, Hettle R, Harty G, Wong SL. Siddiqui MK, et al. Among authors: wong sl. Curr Med Res Opin. 2018 Aug;34(8):1361-1371. doi: 10.1080/03007995.2017.1407303. Epub 2017 Nov 28. Curr Med Res Opin. 2018. PMID: 29149804

4

Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.

Hettle R, Harty G, Wong SL. Hettle R, et al. Among authors: wong sl. J Med Econ. 2018 Jul;21(7):676-686. doi: 10.1080/13696998.2018.1461630. Epub 2018 Apr 16. J Med Econ. 2018. PMID: 29618273 Free article.

5

Identifying Patients With Relapsing-Remitting Multiple Sclerosis Using Algorithms Applied to US Integrated Delivery Network Healthcare Data.

Van Le H, Le Truong CT, Kamauu AWC, Holmén J, Fillmore C, Kobayashi MG, Martin C, Sabidó M, Wong SL. Van Le H, et al. Among authors: wong sl. Value Health. 2019 Jan;22(1):77-84. doi: 10.1016/j.jval.2018.06.014. Epub 2018 Aug 9. Value Health. 2019. PMID: 30661637 Free article.

6

Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing-remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches.

Berardi A, Siddiqui MK, Treharne C, Harty G, Wong SL. Berardi A, et al. Among authors: wong sl. Curr Med Res Opin. 2019 Aug;35(8):1371-1378. doi: 10.1080/03007995.2019.1585779. Epub 2019 Mar 29. Curr Med Res Opin. 2019. PMID: 30786783

7

Impact of Nonrandomized Dropout on Treatment Switching Adjustment in the Relapsing-Remitting Multiple Sclerosis CLARITY Trial and the CLARITY Extension Study.

Gorrod HB, Latimer NR, Damian D, Hettle R, Harty GT, Wong SL. Gorrod HB, et al. Among authors: wong sl. Value Health. 2019 Jul;22(7):772-776. doi: 10.1016/j.jval.2018.11.015. Epub 2019 May 17. Value Health. 2019. PMID: 31277823 Free article. Clinical Trial.

8

Assessing the Long-Term Effectiveness of Cladribine vs. Placebo in the Relapsing-Remitting Multiple Sclerosis CLARITY Randomized Controlled Trial and CLARITY Extension Using Treatment Switching Adjustment Methods.

Bell Gorrod H, Latimer NR, Damian D, Hettle R, Harty GT, Wong SL. Bell Gorrod H, et al. Among authors: wong sl. Adv Ther. 2020 Jan;37(1):225-239. doi: 10.1007/s12325-019-01140-z. Epub 2019 Nov 7. Adv Ther. 2020. PMID: 31701485 Clinical Trial.

9

Patients With High-disease-activity Relapsing-Remitting Multiple Sclerosis in Real-world Clinical Practice: A Population-based Study in Sweden.

Spelman T, Freilich J, Anell B, Wong SL, Hillert J. Spelman T, et al. Among authors: wong sl. Clin Ther. 2020 Feb;42(2):240-250. doi: 10.1016/j.clinthera.2019.11.018. Epub 2019 Dec 31. Clin Ther. 2020. PMID: 31899001

10

Summarizing Patient Preferences for the Competitive Landscape of Multiple Sclerosis Treatment Options.

Jonker MF, Donkers B, Goossens LMA, Hoefman RJ, Jabbarian LJ, de Bekker-Grob EW, Versteegh MM, Harty G, Wong SL. Jonker MF, et al. Among authors: wong sl. Med Decis Making. 2020 Feb;40(2):198-211. doi: 10.1177/0272989X19897944. Epub 2020 Feb 17. Med Decis Making. 2020. PMID: 32065023

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

796 results

Search Page

Filters